Quinidine and haloperidol as modifiers of CYP3A4 activity: Multisite kinetic model approach

被引:84
作者
Galetin, A
Clarke, SE
Houston, JB
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
[2] GlaxoSmithKline, Dept Mech & Extrapolat Technol, Welwyn Garden City, Herts, England
关键词
D O I
10.1124/dmd.30.12.1512
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The selection of appropriate substrates for investigating the potential inhibition of CYP3A4 is critical as the magnitude of effect is often substrate-dependent, and a weak correlation is often observed among different CYP3A4 substrates. This feature has been attributed to the existence of multiple binding sites and, therefore, relatively complex in vitro data modeling is required to avoid erroneous evaluation and to allow prediction of drug-drug interactions. This study, performed in lymphoblast-expressed CYP3A4 with oxidoreductase, provides a systematic comparison of the effects of quinidine ( QUI) and haloperidol (HAL) as modifiers of CYP3A4 activity using a selection of CYP3A4 substrates: testosterone (TST), midazolam (MDZ), nifedipine (NIF), felodipine (FEL), and simvastatin (SV). The effect of QUI and HAL on CYP3A4-mediated pathways was substrate-dependent, ranging from potent inhibition of NIF (K-i = 0.25 and 5.3 muM for HAL and QUI, respectively), weak inhibition (TST), minimal effect ( HAL on MDZ/SV) to QUI activation of FEL and SV metabolism. Inhibition of TST metabolite formation occurred but its autoactivation properties were maintained, indicating binding of a QUI/HAL molecule to a distinct effector site. Various multisite kinetic models have been applied to elucidate the mechanism of the drug-drug interactions observed. Kinetic models with two substrate-binding sites have been found to be appropriate to a number of interactions, provided the substrates show hyperbolic (MDZ, FEL, and SV) or substrate inhibition kinetic properties ( NIF). In contrast, a three-site model approach is required for TST, a substrate showing positive cooperativity in its binding to CYP3A4.
引用
收藏
页码:1512 / 1522
页数:11
相关论文
共 38 条
[1]  
Domanski TL, 2000, J PHARMACOL EXP THER, V293, P585
[2]   Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity [J].
Domanski, TL ;
He, YA ;
Khan, KK ;
Roussel, F ;
Wang, QM ;
Halpert, JR .
BIOCHEMISTRY, 2001, 40 (34) :10150-10160
[3]  
Feierman DE, 1996, DRUG METAB DISPOS, V24, P932
[4]   Analysis of human cytochrome P450 3A4 cooperativity: Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics [J].
Harlow, GR ;
Halpert, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6636-6641
[5]   Elucidation of distinct ligand binding sites for cytochrome P450 3A4 [J].
Hosea, NA ;
Miller, GP ;
Guengerich, FP .
BIOCHEMISTRY, 2000, 39 (20) :5929-5939
[6]  
Houston JB, 2000, DRUG METAB DISPOS, V28, P246
[7]  
Ito K, 1998, PHARMACOL REV, V50, P387
[8]  
Kenworthy KE, 1999, BRIT J CLIN PHARMACO, V48, P716
[9]  
Kenworthy KE, 2001, DRUG METAB DISPOS, V29, P1644
[10]   Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation [J].
Khan, KK ;
He, YQ ;
Domanski, TL ;
Halpert, JR .
MOLECULAR PHARMACOLOGY, 2002, 61 (03) :495-506